The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism

Abstract

Aims/hypothesisPotentiation of glucose-induced insulin secretion is the main mechanism of exenatide (EXE) antidiabetic action, however, increased glucose utilization by peripheral tissues has been also reported. We here studied the effect of EXE on glucose uptake by skeletal muscle cells.Methods2-deoxy-glucose (2DG) uptake and intracellular signal pathways were measured in rat L6 skeletal muscle myotubes exposed to 100 nmol/l EXE for up to 48 h. Mechanisms of EXE action were explored by inhibiting AMPK activity with compound C (CC, 40 μmol/l) or siRNAs (2 μmol/l).ResultsTime course experiments show that EXE increases glucose uptake up to 48 h achieving its maximal effect, similar to that induced by insulin, after 20 min (2- vs 2.5-fold-increase, respectively). Differently from insulin, EXE does not stimulate: (i) IR β-subunit- and IRS1 tyrosine phosphorylation and binding to p85 regulatory subunit of PI-3kinase; (ii) AKT activation; and (iii) ERK1/2 and JNK1/2 phosphorylation. Conversely, EXE increases phosphorylation of α-subunit of AMPK at Thr172 by 2.5-fold (p < 0.01). Co-incubation of EXE and insulin does not induce additive effects on 2DG-uptake. Inhibition of AMPK with CC, and reduction of AMPK protein expression by siRNA, completely abolish EXE-induced 2DG-uptake. Liraglutide, another GLP-1 receptor agonist, also stimulates AMPK phosphorylation and 2DG-uptake. Moreover, EXE stimulates 2DG-uptake also by L6 myotubes rendered insulin-resistant with methylglyoxal. Finally, EXE also induces glucose transporter Glut-4 translocation to the plasma membrane.Conclusions/interpretationIn L6 myotubes, EXE and liraglutide increase glucose uptake in an insulin-independent manner by activating AMPK.Electronic supplementary materialThe online version of this article (doi:10.1186/s12967-016-0985-7) contains supplementary material, which is available to authorized users.

Fucoidan ameliorates pancreatic β‐cell death and impaired insulin synthesis in streptozotocin‐treated β cells and mice via a Sirt‐1‐dependent manner

“…GLP‐1 has an advantage to stimulate glucose‐dependent insulin secretion, therefore avoiding the side effects such as hypoglycemia that traditional diabetic drugs may cause, suggesting that GLP‐1R‐activating reagents are potential agents for alleviating T2DM and its associated complications . Activation of ERK1/2 and PI3K/Akt, and AMPK/Sirt‐1 signaling has been considered as major mechanisms accounting for the beneficial effects of GLP‐1R . Accordingly, induction of GLP‐1R can enhance the transcription of PDX‐1 through activation of these signaling pathways.…”

Diabetes pharmacotherapy and effects on the musculoskeletal system

“…GLP‐1 has been shown to increase glucose uptake in skeletal muscle, an effect that is mediated by nitric oxide . Exendin‐4 has been shown to enhance glucose transport in skeletal muscle of diabetic rats and both exenatide and liraglutide promote glucose uptake in skeletal muscle through AMPK activation . Exendin‐4 increases glycogen synthase activity and glucose incorporation into glycogen and stimulates glucose utilization and oxidation in muscle .…”

Exendin‐4 enhances radiation response of prostate cancer

“…Previous studies revealed that exendin‐4 could inhibit lipid synthesis of hepatic cells by upregulation of AMPK phosphorylation . Exenatide and liraglutide activated glucose transport by an AMPK‐dependent mechanism . Liraglutide ameliorated palmitate‐induced endothelial dysfunction through activating AMPK and reversing leptin resistance .…”